Skip to main content

What the FDA labels say about taking them together

Glycerol phenylbutyrate and haloperidol

Glycerol phenylbutyrate's FDA label of October 29, 2025 names haloperidol in its drug interactions section; the haloperidol labels PlainMeds reads (2) do not name glycerol phenylbutyrate. The glycerol phenylbutyrate label: “DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely.”

Check it at the source: the glycerol phenylbutyrate FDA label on DailyMed (effective October 29, 2025, Horizon Therapeutics USA, Inc.); the haloperidol FDA label on DailyMed (effective April 23, 2026, PD-Rx Pharmaceuticals, Inc.).

What does the glycerol phenylbutyrate label say about haloperidol?

Glycerol phenylbutyrate label, drug interactions

DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely.

Source: FDA drug label (Ravicti), Horizon Therapeutics USA, Inc., effective October 29, 2025 (SPL set 900e7dc0-9afe-4f50-80de-90567bb78519), via openFDA; the full label on DailyMed

What does the haloperidol label say about glycerol phenylbutyrate?

Haloperidol's label (effective April 23, 2026) and its 1 other brand-application label do not name glycerol phenylbutyrate in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Haloperidol), PD-Rx Pharmaceuticals, Inc., effective April 23, 2026 (SPL set 533b0b4c-cbd6-4ec0-a333-8b04b5b43a1d), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

7Glycerol phenylbutyrate generic labelers
41Haloperidol generic labelers
Glycerol phenylbutyrateHaloperidol
Labeled forn/aSchizophrenia
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$15.60 per mL 100 mg/mL vial
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?